Moomoo AIのまとめ
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, have filed a Schedule 13G with the United States Securities and Exchange Commission on April 5, 2024, indicating a shared voting and dispositive power over 114,775 shares of Avalo Therapeutics, Inc. This represents 9.99% of the company's class of common stock. The filing, which is required due to the acquisition of shares that meet the threshold for reporting, states that the shares include 1,940.68125 Series C Non-Voting preferred stock and 1,164,408 warrants, both subject to a beneficial ownership limitation of 9.99%. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics, Inc. and were not held in connection with any transaction having that purpose or effect. The principal business offices of the reporting persons are located in Delaware, the Cayman Islands, and the United States, respectively.
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, have filed a Schedule 13G with the United States Securities and Exchange Commission on April 5, 2024, indicating a shared voting and dispositive power over 114,775 shares of Avalo Therapeutics, Inc. This represents 9.99% of the company's class of common stock. The filing, which is required due to the acquisition of shares that meet the threshold for reporting, states that the shares include 1,940.68125 Series C Non-Voting preferred stock and 1,164,408 warrants, both subject to a beneficial ownership limitation of 9.99%. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics, Inc. and were not held in connection with any transaction having that purpose or effect. The principal business offices of the reporting persons are located in Delaware, the Cayman Islands, and the United States, respectively.
Deep Track Capital, LP及びDeep Track Biotechnology Master Fund, Ltd.、David Kroinは、2024年4月5日に米国証券取引委員会に対してスケジュール13Gを提出し、Avalo Therapeutics, Inc.の114,775株に対する共有投票権と取得力を示しました。これは、同社の普通株式クラスの9.99％に相当します。報告書は、報告のための閾値を満たす株式の取得により必要とされるものであり、株式にはベネフィシャル・オーナーシップ・リミテーションの1,940.68125シリーズC非投票優先株式および1,164,408ワラン...すべて展開
Deep Track Capital, LP及びDeep Track Biotechnology Master Fund, Ltd.、David Kroinは、2024年4月5日に米国証券取引委員会に対してスケジュール13Gを提出し、Avalo Therapeutics, Inc.の114,775株に対する共有投票権と取得力を示しました。これは、同社の普通株式クラスの9.99％に相当します。報告書は、報告のための閾値を満たす株式の取得により必要とされるものであり、株式にはベネフィシャル・オーナーシップ・リミテーションの1,940.68125シリーズC非投票優先株式および1,164,408ワラントが含まれていることを述べています。報告書は、証券がAvalo Therapeutics, Inc.の支配権を変更または影響を与える目的で取得されたものではなく、またそのような目的または効果を持つ取引と関連して保持されたものではないことを主張しています。報告者の本社所在地は、それぞれデラウェア州、ケイマン諸島、および米国にあります。
役に立った
役に立たない